Human Organoids Market to Hit USD 2.33 Billion by 2029 with 14.4% CAGR | MarketsandMarkets™
DELRAY BEACH, Fla., Dec. 4, 2024 /PRNewswire/ -- The global human organoids market is valued at an estimated USD 1.19 billion in 2024 and is projected to reach USD 2.33 billion by 2029 at a CAGR of 14.4% during the forecast period. The growth in the human organoids market is mainly driven by several important factors. This primarily includes the advancement in stem cell technology that allows scientists to develop personalized organoids for every patient. Such a development helps in accurate modeling of diseases and drugs testing process. Besides this, the advancement in bioprinting and 3D cell culture has further augmented the development and handling of organoids. It not only speeds up the process of production but also enhances the functionality of the organoids, thus it is more effective for research and therapeutic purposes. In cancer research, organoids play an important role today as it can be used very effectively as a model to study the process of growing a tumor and its response to treatment. All these factors are driving expansion of the human organoids market.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171046468
Browse in-depth TOC on "Human Organoids Market"
543 - Tables
51 - Figures
426 - Pages
The market is gaining more attention in human organoids amid the major technological developments, new regulatory requirements, and growing demand for alternatives of animal models. For instance, in 2022, the FDA Modernization Act 2.0 came into effect, which permitted the FDA to consider data outside of the classical conduct of animal studies. This is a major step forward in terms of the developments noticed during the last few decades in biological and technological research, especially concerning cell-based methods such as human induced pluripotent stem cells (iPSCs) and organoids. The Act will accelerate the growth for alternatives to animal testing and will highly benefit the human organoids market. The need for the absence of animal testing in drug development drives the researchers to adopt organoids that better depict the systems of human biology. This will lead to a clearer regulatory pathway, accelerate drug development, and promote better ethical standards in research.
Based on product, the human organoids market is segmented into liver models, kidney models, pancreas models, colorectal models, heart models, lung models, other products. The liver segment accounted for the largest share in the human organoids market in 2023. Liver organoids are important for conducting drug safety and efficacy testing as well as researching diseases of the liver like hepatitis and cirrhosis. Advances such as patient-specific models make them highly relevant both in research and in personalized medicine and firmly place them as indispensable tools within the pharmaceutical industry.
Categorized by type, the human organoids market is segmented into ready-to-use products and customizable products. In 2023, ready-to-use products segment accounted for the largest share of the human organoids market. The market for ready-to-use organoids is already well-established. Researchers and pharmaceutical companies have access to many different commercially available products relatively easily, which would make it easier for such organizations to integrate organoids into research. Customized organoids might not always be that accessible, and their development might be more complicated and more complex. Thus, the simplicity and replicability of using pre-made organoids typically make it more desirable for the researchers who seek reliable and efficient instruments for conducting their experiments.
Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=171046468
The key players in this market are Thermo Fisher Scientific Inc. (US), Corning Incorporated (US), Merck KGaA (Germany), BioIVT (US), HUB Organoids BV (Netherlands), BICO (Sweden), BeCytes Biotechnologies SL (Spain), InSphero (Switzerland), GBA Group (Germany), Kirkstall Ltd. (UK), MIMETAS BV (Netherlands), Neuromics (US), PRIMACYT Cell Culture Technology GmbH (Germany), STEMCELL Technologies (Canada), ACROBiosystems (China), Biopredic International (France), CN Bio Innovations Ltd. (UK), CYPRIO (France), Emulate, Inc. (US), Kerafast, Inc. (US), Pandorum Technologies Pvt. Ltd (India), CYFUSE BIOMEDICAL K.K. (Japan), NeyroblastGX LLC (US), 3Dnamics Inc. (US), and DefiniGEN Limited (UK). The market players have adopted various strategies such as development of advanced products, partnerships, expansions, and acquisitions to strengthen their position in the human organoids. The organic and inorganic strategies have helped the market players expand globally by providing human organoids.
Thermo Fisher Scientific develops and manufactures, as well as markets, analytical instruments, reagents and consumables, equipment, and software products. The company operates in four business segments: Analytical Instruments, Specialty Diagnostics, Life Sciences Solutions, and Laboratory Products and Biopharma Services. It offers human organoid products under its Life Sciences Solutions segment. The company is well presented in more than 70 countries across North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa. It invests in research and development to bring out new and innovative products. In addition, it focuses on partnerships for strengthening business capabilities and enhancing market share.
Corning Incorporated is a multinational corporation based in the US, primarily focused on manufacturing of specialty glass and ceramic technology alongside other allied materials & technologies that include advanced industrial and scientific optics. The corporation operates 124 manufacturing facilities in 15 countries and is organized into five broad-based divisions. These are - the Optical Communications Division, the Display Technologies Division, the Specialty Materials Division, the Environmental Technologies Division, and the Life Sciences Division. Through the Life Sciences division, Corning manufactures human organoid products. Focused on R&D, the company is keen on rolling out new and advanced technological products. It works with a variety of partners, including research institutions and customers, to help speed up the processes of research and development. This helps build its business, improves its technologies and products, enables it to enter new markets, and nurtures relationships with customers over time.
BiolVT is a biobanking company, focused on designing, manufacturing, and providing biological specimens such as human tissues and cell products, blood, as well as other biofluids to clients across North America, Asia Pacific, Europe, and the Middle East & Africa. BiolVT is a prominent company in the human organoids market and has developed a multitude of tissue models of organs. The portfolio is so diverse that researchers get access to models specifically customized for research purposes, such as drug testing and modeling of disease. With a global network of collection sites and collaborations, BiolVT is manufacturing organoid models compatible for diversified clinical conditions. The company focuses on Inorganic strategies to hold a strong foothold in the market. To maintain a solid presence in the industry, the company focuses on inorganic strategies. For instance, in July 2021, BiolVT acquired Tissue Solutions Ltd. virtual biobank; the acquisition expanded BiolVT's global network through the addition of 150 collection sites to the network while providing improved access to high-quality control and disease state biospecimens and increased global reach for prospective collections.
For more information, Inquire Now!
Related Reports:
Top 10 Medical Device Technologies Market
Get access to the latest updates on Human Organoids Companies and Human Organoids Market Size
About MarketsandMarkets™:
MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Logo: https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg
View original content:https://www.prnewswire.co.uk/news-releases/human-organoids-market-to-hit-usd-2-33-billion-by-2029-with-14-4-cagr--marketsandmarkets-302322071.html